cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.8869871.v1
title: Database file - ODAEL dataset variant (MS COCO)

description: This database represents a variant of the MITOS_WSI_CCMCT data set. It includes all manually labelled mitotic figures as well as hard examples as defined by human experts based on a cell classifier and additionally mitotic figures that were found by a deep learning model and assessed by two experts.
DOI: 10.6084/m9.figshare.8869874.v1
title: Database file - HEAEL dataset variant (MS COCO)

description: This database represents a variant of the MITOS_WSI_CCMCT data set. It includes all manually labelled mitotic figures as well as hard examples as defined by human experts based on a cell classifier.
DOI: 10.6084/m9.figshare.8869865.v1
title: Database file - ODAEL dataset variant (SlideRunner)

description: This database represents a variant of the MITOS_WSI_CCMCT data set. It includes all manually labelled mitotic figures as well as hard examples as defined by human experts based on a cell classifier and additionally mitotic figures that were found by a deep learning model and assessed by two experts.
DOI: 10.6084/m9.figshare.8869868.v1
title: Database file - MEL dataset variant (SlideRunner)

description: This database represents a variant of the MITOS_WSI_CCMCT data set. It includes all manually labelled mitotic figures.
DOI: 10.6084/m9.figshare.8869859
title: Supplementary Material for: No Effect of Genome-Wide Significant Schizophrenia Risk Variation at the <b><i>DRD2</i></b> Locus on the Allelic Expression of <b><i>DRD2</i></b> in Postmortem Striatum

description: A genome-wide significant association has been reported between non-coding variants at the dopamine D2 receptor (<i>DRD2</i>) gene locus and schizophrenia. However, effects of identified schizophrenia risk alleles on <i>DRD2</i> function are yet to be demonstrated. Using highly sensitive measures of allele-specific expression, we have assessed <i>cis</i>-regulatory effects associated with genotype at lead SNP rs2514218 on <i>DRD2</i>expression in the adult human striatum. No significant differences were observed in the extent of allelic expression imbalance between samples that were genomic heterozygotes for rs2514218 (where <i>cis</i>-regulatory effects of the risk allele are compared with those of the non-risk allele within individual subjects) and samples that were homozygous for rs2514218 (where <i>cis</i>-regulatory effects of this SNP on each expressed <i>DRD2</i> allele will be equal). We therefore conclude that rs2514218 genotype is not associated with large effects on overall <i>DRD2</i> RNA expression, at least in postmortem adult striatum. Alternative explanations for the genetic association between this variant and schizophrenia include effects on <i>DRD2</i> that are transcript specific, restricted to minor <i>DRD2</i>-expressing cell populations or elicited only under certain physiological circumstances, or mediation through effects on another gene (or genes) at the locus.
DOI: 10.6084/m9.figshare.8869841
title: Whole Slide Image of Canine Mast Cell Tumor, ID 3

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869844
title: Whole Slide Image of Canine Mast Cell Tumor, ID 20

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869862
title: Database file - MEL dataset variant (MS COCO)

description: This database represents a variant of the MITOS_WSI_CCMCT data set. It includes all manually labelled mitotic figures.
DOI: 10.6084/m9.figshare.8869862.v1
title: Database file - MEL dataset variant (MS COCO)

description: This database represents a variant of the MITOS_WSI_CCMCT data set. It includes all manually labelled mitotic figures.
DOI: 10.6084/m9.figshare.8869838
title: Whole Slide Image of Canine Mast Cell Tumor, ID 26

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869844.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 20

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869832
title: Whole Slide Image of Canine Mast Cell Tumor, ID 29

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869835
title: Whole Slide Image of Canine Mast Cell Tumor, ID 27

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869829
title: Whole Slide Image of Canine Mast Cell Tumor, ID 24

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869838.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 26

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869826
title: Whole Slide Image of Canine Mast Cell Tumor, ID 25

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869832.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 29

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869835.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 27

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869823
title: Whole Slide Image of Canine Mast Cell Tumor, ID 35

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869829.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 24

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869820
title: Whole Slide Image of Canine Mast Cell Tumor, ID 14

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869826.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 25

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869820.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 14

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869814
title: Whole Slide Image of Canine Mast Cell Tumor, ID 19

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869817
title: Whole Slide Image of Canine Mast Cell Tumor, ID 21

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869823.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 35

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869808
title: Whole Slide Image of Canine Mast Cell Tumor, ID 9

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869811
title: Whole Slide Image of Canine Mast Cell Tumor, ID 8

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869814.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 19

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869817.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 21

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869805
title: Whole Slide Image of Canine Mast Cell Tumor, ID 17

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869808.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 9

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869811.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 8

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869796
title: Whole Slide Image of Canine Mast Cell Tumor, ID 15

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869799
title: Whole Slide Image of Canine Mast Cell Tumor, ID 22

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869802
title: Whole Slide Image of Canine Mast Cell Tumor, ID 23

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869805.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 17

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869799.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 22

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869802.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 23

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869790
title: Whole Slide Image of Canine Mast Cell Tumor, ID 6

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869784
title: Whole Slide Image of Canine Mast Cell Tumor, ID 31

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869787
title: Whole Slide Image of Canine Mast Cell Tumor, ID 7

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869781
title: Whole Slide Image of Canine Mast Cell Tumor, ID 18

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869787.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 7

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869790.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 6

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869778
title: Whole Slide Image of Canine Mast Cell Tumor, ID 34

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869781.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 18

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869769
title: Whole Slide Image of Canine Mast Cell Tumor, ID 1

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869772
title: Whole Slide Image of Canine Mast Cell Tumor, ID 28

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869775
title: Whole Slide Image of Canine Mast Cell Tumor, ID 11

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869772.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 28

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869778.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 34

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869766
title: Whole Slide Image of Canine Mast Cell Tumor, ID 30

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869763
title: Whole Slide Image of Canine Mast Cell Tumor, ID 4

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869763.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 4

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869661
title: Whole Slide Image of Canine Mast Cell Tumor, ID 12

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869766.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 30

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869661.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 12

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869652
title: Whole Slide Image of Canine Mast Cell Tumor, ID 2

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869655
title: Whole Slide Image of Canine Mast Cell Tumor, ID 32

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869658
title: Whole Slide Image of Canine Mast Cell Tumor, ID 36

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869649
title: Whole Slide Image of Canine Mast Cell Tumor, ID 13

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869655.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 32

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869658.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 36

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869652.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 2

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869649.v1
title: Whole Slide Image of Canine Mast Cell Tumor, ID 13

description: Whole Slide Image of Canine Mast Cell Tumor, part of the MITOS_WSI_CCMCT data set.
DOI: 10.6084/m9.figshare.8869625
title: Supplementary Material for: Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma

description: <b><i>Background/Aim:</i></b> We evaluated clinical factors related to improved prognosis of unresectable hepatocellular carcinoma patients (u-HCC), who were treated with tyrosine kinase inhibitor (TKI) sequential therapy, including lenvatinib (LEN). <b><i>Materials/Methods:</i></b> We enrolled 84 u-HCC cases treated with TKIs including LEN from March 2018 to January 2019 (median age 71 years, 63 males, Child-Pugh score (CPS) 5/6/7 = 62/21/1, tumor-node-metastasis stage of Liver Cancer Study Group of Japan 6th (TNM-LCSGJ) II/III/IVa/IVb = 12/30/5/37, Barcelona Clinic Liver Cancer stage B/C = 33:51). Clinical findings at introduction of the initial TKI were retrospectively evaluated. <b><i>Results:</i></b> The median albumin-bilirubin (ALBI) score at introduction of the initial TKI (sorafenib [SOR]/LEN = 80/4) was –2.56, and the past number of transarterial catheter chemoembolization was 3 (IQR: 2–5) (second-line: regorafenib [REG]/LEN/SOR = 31/49/4, third-line: LEN/REG = 31:1). The total period of administration with TKIs showed a good relationship with overall survival (OS) (<i>r</i> = 0.946, 95% confidence interval [CI]: 0.918–0.965, <i>p</i> &lt; 0.001). The prognosis of the entire cohort was good (estimated median survival time: 46.4 months, 1-/2-/3-year OS rate [OSR] = 87.7/63.0/57.2%). A modified-ALBI grade (mALBI) of 2b (ALBI score &gt;–2.27) was the only significant factor at the start of the initial TKI for poor prognosis (hazard ratio 2.319, 95% CI: 1.064–5.052, <i>p</i> = 0.034), while CPS (≥6) was not. Although there was no significant difference in TNM-LCSGJ (<i>p</i> = 0.213), the prognosis of patients with mALBI 1/2a (<i>n</i> = 66) showed better prognosis as compared to those with mALBI 2b (<i>n</i> = 18) (1-year/2-year/3-year OSR = 89.1/69.8/66% vs. 82.4/47.1/23.5%, <i>p</i> = 0.029). <b><i>Conclusion:</i></b> Good hepatic function (mALBI 1/2a) at introduction of the initial TKI is a requirement for improved prognosis of u-HCC undergoing TKI sequential therapy.
DOI: 10.6084/m9.figshare.8869625.v1
title: Supplementary Material for: Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma

description: <b><i>Background/Aim:</i></b> We evaluated clinical factors related to improved prognosis of unresectable hepatocellular carcinoma patients (u-HCC), who were treated with tyrosine kinase inhibitor (TKI) sequential therapy, including lenvatinib (LEN). <b><i>Materials/Methods:</i></b> We enrolled 84 u-HCC cases treated with TKIs including LEN from March 2018 to January 2019 (median age 71 years, 63 males, Child-Pugh score (CPS) 5/6/7 = 62/21/1, tumor-node-metastasis stage of Liver Cancer Study Group of Japan 6th (TNM-LCSGJ) II/III/IVa/IVb = 12/30/5/37, Barcelona Clinic Liver Cancer stage B/C = 33:51). Clinical findings at introduction of the initial TKI were retrospectively evaluated. <b><i>Results:</i></b> The median albumin-bilirubin (ALBI) score at introduction of the initial TKI (sorafenib [SOR]/LEN = 80/4) was –2.56, and the past number of transarterial catheter chemoembolization was 3 (IQR: 2–5) (second-line: regorafenib [REG]/LEN/SOR = 31/49/4, third-line: LEN/REG = 31:1). The total period of administration with TKIs showed a good relationship with overall survival (OS) (<i>r</i> = 0.946, 95% confidence interval [CI]: 0.918–0.965, <i>p</i> &lt; 0.001). The prognosis of the entire cohort was good (estimated median survival time: 46.4 months, 1-/2-/3-year OS rate [OSR] = 87.7/63.0/57.2%). A modified-ALBI grade (mALBI) of 2b (ALBI score &gt;–2.27) was the only significant factor at the start of the initial TKI for poor prognosis (hazard ratio 2.319, 95% CI: 1.064–5.052, <i>p</i> = 0.034), while CPS (≥6) was not. Although there was no significant difference in TNM-LCSGJ (<i>p</i> = 0.213), the prognosis of patients with mALBI 1/2a (<i>n</i> = 66) showed better prognosis as compared to those with mALBI 2b (<i>n</i> = 18) (1-year/2-year/3-year OSR = 89.1/69.8/66% vs. 82.4/47.1/23.5%, <i>p</i> = 0.029). <b><i>Conclusion:</i></b> Good hepatic function (mALBI 1/2a) at introduction of the initial TKI is a requirement for improved prognosis of u-HCC undergoing TKI sequential therapy.
DOI: 10.6084/m9.figshare.8869598
title: Ledesma_et_al_2019_ECE_Dataset.xlsx

description: Data related to article entitled "Future hydrological constraints of the Montseny brook newt (<i>Calotriton arnoldi</i>) under changing climate and vegetation cover", published in Ecology and Evolution.<br>
DOI: 10.6084/m9.figshare.8869592
title: Supplementary Material for: Percent Consonant Correct as an Outcome Measure for Cleft Speech in an Intervention Study

description: <b><i>Background/Aims:</i></b> Percent consonant correct (PCC) was originally described by Shriberg and Kwiatkowski [J Speech Hear Disord. 1982 Aug;47(3):256–70] as a severity metric for phonological speech disorders, and has been adapted and used in many studies on speech sound disorders. It is well-recognized that cleft speech is complex, consisting of several interacting parameters assessed simultaneously, with error sounds not in the listener’s own language. In speech outcome studies, narrow phonetic transcription and the reporting of intra- and inter-rater reliability are acknowledged as the gold standard. However, cleft speech brings special challenges to this task, as complex speech disorders are known to be associated with low transcriber agreement. Recent studies informed the decision to use PCC as the primary outcome measure in a cleft speech intervention study, given its common usage and familiarity. The aim was to specifically evaluate the intra- and inter-rater reliability of PCC in an intervention study, in contrast to other types of speech outcome studies. <b><i>Methods:</i></b> Two trained and experienced listeners analyzed 119 recordings, randomly selected from five data points before, during, and following intervention. The PCC score was separately calculated for words and sentences/phrases. <b><i>Results:</i></b> Using intraclass correlations (ICCs), Phase 1 results showed poor reliability for targets elicited for words (ICC = 0.07) and sentences/phrases (ICC = 0.42). Differences in classification of errors as glottal stops and consonant deletion accounted for this. Following further training, a second reliability study was undertaken showing improvement in the number of targets elicited in words (ICC = 0.85) and sentences/phrases (ICC = 0.94). There was very good inter-rater reliability for the PCC score on the word dataset (ICC = 0.9) and the sentence dataset (ICC = 0.88). Very good intra-rater reliability (ICC = 1.0) was found for the PCC score in both words and sentences/phrases for each listener. One listener consistently gave higher modified PCC scores. <b><i>Conclusions:</i></b> In cleft speech intervention studies, reliability of the number of targets elicited should be reported. Listeners need to distinguish between glottal articulation and consonant deletion, in order that the PCC score is meaningful. Attention should be paid to where listeners are reliable, but their pattern of scores consistently differs but in a consistent way. More research is needed on measuring the resolution of articulation difficulties in cleft intervention studies.
DOI: 10.6084/m9.figshare.8869586
title: Temporal dynamics of mycorrhizal fungal communities and co-associations with grassland plant communities following experimental manipulation of rainfall

description: The data contains 4 files:<br>AM fungal community matrix, plant community matrix and treatment table (samples description), to correlate AM fungal community to plant community, and a fasta file containing DNA sequences for each fungal operational taxonomic unit.<br><br>OTUmatrix.csv<br>AM fungal community matrix. Matrix containing number of reads of Operational Taxonomic Units (OTU) of Glomeromycota Fungi for each molecular sample; ‘sample’ (sample ID) and OTU (other columns).<br><br>soilData.csv<br>Treatment table, description of each sample. Contains information on the treatments associated with each sample. Columns description: ‘sample’ (sample ID, which is the sample number used in the OTUmatrix), ‘Treatment’ (watering treatment applied in the plot from which the sample was collected), ‘Plot’ (plot number from which the sample was collected), ‘x.coord.m’ (X coordinates of the plots, for spatial analyses; values are distance in meters from plot 1), ‘y.coord.m’ (Y coordinates of the plots, for spatial analyses; values are distance in meters from plot 1), ‘Year’ (year of sample collection), ‘Season’ (season of sample collection), ‘Season.Year’ (sampling date), ‘month’ (number of month since the establishment of the experimental platform; for temporal analyses), ‘batch’ (<br><br>plantMATRIX.csv<br>Plant community matrix. Matrix containing sample description and biomass (grams) of each plant species for each sample. Columns description: ‘soilID’ (corresponding sample ID from the soilData and OTUmatrix), ‘plot’ (plot number from which the sample was collected), ‘year’ (year of sample collection), ‘month’ (month of the year) ,‘season’ (season of sample collection), ‘Season.Year’ (sampling date), ‘treatment’ (watering treatment applied in the plot from which the sample was collected), next columns contain plant species data.<br>